Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: LON:SUMM
- CUSIP: N/A
- Web: N/A
- Market Cap: £111.4 million
- Outstanding Shares: 61,891,000
- 50 Day Moving Avg: GBX 178.86
- 200 Day Moving Avg: GBX 179.73
- 52 Week Range: GBX 88 - GBX 262
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: £2.38 million
- Price / Sales: 46.81
- Book Value: GBX (0.06) per share
- Price / Book: -30.00
- Average Volume: 55,516 shs.
Frequently Asked Questions for Summit Therapeutics PLC (LON:SUMM)
What is Summit Therapeutics PLC's stock symbol?
Summit Therapeutics PLC trades on the London Stock Exchange (LON) under the ticker symbol "SUMM."
Who are some of Summit Therapeutics PLC's key competitors?
Some companies that are related to Summit Therapeutics PLC include Mortgage Advice Bureau (Holdings) PLC (MAB1), Dotdigital Group plc (DOTD), Non-Standard Finance PLC (NSF), Arbuthnot Banking Group Plc (ARBB), Falcon Oil & Gas Ltd (FOG), McKay Securities plc (MCKS), Mothercare plc (MTC), Liontrust Asset Management PLC (LIO), Mattioli Woods plc (MTW), Mereo BioPharma Group PLC (MPH), Faron Pharmaceuticals Oy (FARN), Sportech plc (SPO), Exillon Energy Plc (EXI), Horizon Discovery Group PLC (HZD), Servelec Group PLC (SERV), IG Design Group PLC (IGR), Anglo Pacific Group plc (APF) and Microgen plc (MCGN).
How do I buy Summit Therapeutics PLC stock?
Shares of Summit Therapeutics PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
How much does a share of Summit Therapeutics PLC stock cost?
One share of Summit Therapeutics PLC stock can currently be purchased for approximately GBX 180.
Consensus Ratings for Summit Therapeutics PLC (LON:SUMM) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Summit Therapeutics PLC (LON:SUMM)
(Data available from 5/28/2015 forward)
|5/16/2017||N+1 Singer||Reiterated Rating||corporate|
Earnings History for Summit Therapeutics PLC (LON:SUMM)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Summit Therapeutics PLC (LON:SUMM)
Current Year EPS Consensus Estimate: $-38.45 EPS
Dividend History for Summit Therapeutics PLC (LON:SUMM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Summit Therapeutics PLC (LON:SUMM)Insider Trades by Quarter for Summit Therapeutics PLC (LON:SUMM)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/17/2015||Valerie Andrews||Insider||Buy||10,500||GBX 145||£15,225|
Headline Trends for Summit Therapeutics PLC (LON:SUMM)
Latest Headlines for Summit Therapeutics PLC (LON:SUMM)
Summit Therapeutics PLC (SUMM) Chart for Sunday, May, 28, 2017